EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience

Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Charalampos Filippatos, Sotirios Maganas, Despina Fotiou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Nikolaos Kanellias, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Efstathios Kastritis und 2 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.08.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Ioannis Ntanasis-Stathopoulos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Multiple Myeloma, Dexamethasone, Cyclophosphamide, Thalidomide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Pomalidomide, a third-generation IMiD, has shown efficacy in relapsed/refractory multiple myeloma (RRMM). The addition of cyclophosphamide to pomalidomide and dexamethasone (PCd) has been explored as a potential therapeutic option in this challenging setting. METHODS: We conducted a retrospective analysis of RRMM patients treated with PCd in the Department of Clinical Therapeutics, Athens, Greece. Eligible patients had histologically confirmed MM, received ≥ 1 prior therapy, and experienced disease progression. RESULTS: A total of 45 RRMM patients were treated with PCd in our department, with a median of 2 prior lines of therapy. The median follow-up from the time of diagnosis of symptomatic MM was 7.8 years and it was 21.1 months from the initiation of PCd. The ORR was 46.7% and the DCR was 66.7%. The median TTNT, PFS and OS were 14.6 months, 9.0 months and 21.0 months, respectively. Age, number of prior lines of therapy and exposure to lenalidomide at the immediate prior line did not seem to impact patient outcomes. On the other hand, patients harboring expanded high-risk cytogenetics at MM diagnosis, experienced particularly worse PFS (aHR = 3.08, 95% CI, 1.33-7.17) and DCR (42.9% vs. 77.4%, P = .039), compared to those with no abnormalities. Finally, the most common severe grade 3/4 toxicity was neutropenia. CONCLUSION: The addition of cyclophosphamide to Pd in moderately to heavily pretreated RRMM patients showed promising efficacy, supporting PCd as a potential therapeutic option in real-world clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaDexamethasoneCyclophosphamideThalidomideAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overAdultTreatment OutcomeNeoplasm Recurrence, LocalDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Multiple myelomaSurvivalTriplet

Substanzen

DexamethasonepomalidomideCyclophosphamideThalidomide

Autor:innen und Institutionen

  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul, South Korea.
  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: mgavria@med.uoa.gr.

Zitieren

APA

Ntanasis-Stathopoulos, I., Malandrakis, P., Filippatos, C., Maganas, S., Fotiou, D., Theodorakakou, F., Spiliopoulou, V., Kanellias, N., Migkou, M., Eleutherakis-Papaiakovou, E., Terpos, E., Kastritis, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2025). Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.08.003

Vancouver

Ntanasis-Stathopoulos I, Malandrakis P, Filippatos C, Maganas S, Fotiou D, Theodorakakou F, et al. Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.08.003

BibTeX
@article{NtanasisStathopoulos2025,
  author = {Ntanasis-Stathopoulos, Ioannis and Malandrakis, Panagiotis and Filippatos, Charalampos and Maganas, Sotirios and Fotiou, Despina and Theodorakakou, Foteini and Spiliopoulou, Vasiliki and Kanellias, Nikolaos and Migkou, Magdalini and Eleutherakis-Papaiakovou, Evangelos and Terpos, Evangelos and Kastritis, Efstathios and Dimopoulos, Meletios A and Gavriatopoulou, Maria},
  title = {Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.08.003}
}
Kostenlos starten →